Edgar v. Teva Pharmaceuticals Industries, Ltd.

District Court, D. Kansas·Decided April 14, 2025·No. 2:22-cv-02501·Unknown

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

DENA BURGE, LEIGH HOCKETT, JORDAN FURLAN, CRISTINE RIDEY, PATRICIA SAWCZUK, and ANNE ARUNDEL COUNTY, individually and on behalf of all others similarly situated, Case No. 22-cv-2501-DDC-TJJ

Plaintiffs,

v.

TEVA PHARMACEUTICAL INDUSTRIES, LTD., TEVA PHARMACEUTICALS USA, INC., TEVA PARENTERAL MEDICINES, INC., TEVA NEUROSCIENCE, INC., TEVA SALES & MARKETING, INC., and CEPHALON, INC.,

Defendants.

MEMORANDUM AND ORDER

This matter is before the Court on Defendants’ Motion to Compel Plaintiff Anne Arundel County (“Anne Arundel”) to Designate Additional Custodians (ECF No. 154). Defendants request an order compelling Anne Arundel to designate three additional custodians (all in-house attorneys) for purposes of Phase I document collection and production, and to produce responsive documents from those custodians. Anne Arundel opposes the motion. As explained below, Defendants’ motion is granted with respect to adding in-house counsel Tyler as a Phase I custodian but is otherwise denied. I. Nature of the Case and Discovery Dispute Background Plaintiffs—representing a proposed class—allege Defendants and their co-conspirators entered an unlawful reverse payment settlement and conspired to safeguard their monopoly on Nuvigil, a wakefulness drug with the generic name Armodafinil. Plaintiffs allege Defendants agreed to stay out of the EpiPen market, allowing Mylan and Pfizer to maintain their EpiPen monopoly. In exchange, Plaintiffs contend, Mylan and Pfizer agreed to stay out of the Nuvigil market, allowing Defendants to maintain their Nuvigil monopoly.1 Based on these factual allegations, Plaintiffs assert four claims: (1) a Sherman Act claim; (2) claims for Conspiracy and

Combination in Restraint of Trade under various state laws; (3) claims for Monopolization and Monopolistic Scheme under various state laws; and (4) a Racketeer Influenced and Corrupt Organizations Act (“RICO”) claim.2 Anne Arundel joined the lawsuit as a named plaintiff with the filing of the First Amended Class Action Complaint on June 5, 2023.3 Early in the case, Defendants filed a motion to dismiss Plaintiffs’ claims as barred by the statute of limitations.4 On March 26, 2024, Judge Crabtree denied the motion to dismiss in part, but suggested a bifurcated approach to discovery with initial discovery focused on the pivotal issue of timeliness.5 At the June 13, 2024 scheduling conference, the parties discussed bifurcation of discovery

and indicated their positions on the scope of initial discovery regarding the timeliness issue. The Court thereafter entered an order requiring discovery in Phase I be bifurcated and limited to the timeliness of Plaintiffs’ claims under the applicable statute of limitations (“Timeliness

1 Most of this factual background summary of the case is taken from District Judge Crabtree’s Nov. 6, 2024 Mem. & Order (ECF No. 131). 2 Corrected Second Am. Class Action Compl. (ECF No. 129) filed on Nov. 5, 2024. 3 First Am. Class Action Compl. (ECF No. 42). 4 ECF No. 47. 5 Mar. 26, 2024 Mem. & Order (ECF No. 74) at 40. discovery”).6 On July 15, 2024, the Court entered the Phase I Scheduling Order, which reflected the parties’ agreement that Phase I Timeliness discovery be limited to: [T]he timeliness of Plaintiffs’ claims under the applicable statutes of limitations and any related statute-of-limitations issues, facts, and circumstances, including Defendants’ statute of limitations defense or defenses (and the elements thereof) and the issues of tolling, equitable tolling, and fraudulent concealment (and the elements thereof).7 The Court also entered, upon the parties’ request, an Order Governing the Production of Electronically Stored Information and Documents (“ESI Protocol”) (ECF No. 100). It includes the parties’ agreements with respect to identification and collection of documents, and sets forth the following agreed provision regarding the parties’ identification of Phase I custodians: The parties shall . . . identify those key persons whose files are likely to contain documents relating to the subject matter of Phase I of this litigation, limited to the topics of the timeliness/limitations of Plaintiffs’ claims . . . as set out in the Court’s Order dated June 14, 2024 [D.I. 88] (each a “Phase I Custodian”), along with a description of the proposed Phase I Custodians’ job title and brief description of such person’s responsibilities . . . . The parties retain the right, upon reviewing the initial production of documents, and conducting other investigation and discovery, to request that files from additional Phase I Custodians be searched and meet and confer regarding such request.8 In response to Defendants’ discovery requests and pursuant to the ESI Protocol, Anne Arundel designated as Phase I custodians the following five employees within its Office of Personnel, the department that administers its pharmacy benefits: Benefits Manager Shaquisha Bishop (“Bishop”); Personnel Officer Anne Budowski (“Budowski”); Senior Personnel Analyst & Contracts Administrator Natalie Fretz (“Fretz”); Benefits Contract Consultant/Senior Personnel

6 Order Regarding Phase I Disc. (ECF No. 88). Discovery was also allowed on the issue of personal jurisdiction over Teva Israel. 7 Phase I Sch. Order (ECF No. 92). 8 ESI Protocol (ECF No. 100) ¶ V.A.1 (bold added). Analyst & Contracts Administrator (ret.) Douglass Hart (“Hart”); and Assistant Personnel Officer Kelly Lovett (“Lovett”).9 Defendants raised issues regarding the custodians designated by Anne Arundel and requested additional Phase I custodians be designated.10 At an October 28, 2024 discovery conference, Anne Arundel argued the additional custodians Defendants requested were duplicative

of its five already-named custodians and Defendants’ request was premature as Plaintiffs had not yet produced any documents. The Court agreed Defendants’ request for additional custodians was premature and ordered the parties to further confer after review of Anne Arundel’s substantially completed document productions. The parties provided an update on the status of their custodian dispute at a January 28, 2025 status conference. Anne Arundel substantially completed its production of documents on January 31, 2025.11 After Defendants reviewed that document production, they emailed Anne Arundel renewing their request for additional custodians, stating “Anne Arundel does not appear to have produced any documents that actually are responsive to [Defendants’] RFPs for which it agreed to produce documents.”12 Unable to resolve the dispute after further email exchanges, Defendants timely filed

their motion requesting Anne Arundel designate additional Phase I custodians on February 14, 2025.13

9 See Aug. 30, 2024 Email identifying first four custodians (ECF No. 154-1) at 4–5. Anne Arundel later identified Lovett as a fifth custodian during the parties’ conferral process. See Oct. 8, 2024 Letter (ECF No. 159-1) at 3 n.2. 10 Oct. 25, 2024 Disc. Position Statement (ECF No. 154-2) at 3–4. 11 Anne Arundel’s Opp’n to Defs.’ Mot. (ECF No. 159) at 4. 12 Feb. 10, 2025 Email (ECF No. 154-3) at 5. 13 See Status Conf. Order (ECF No. 150) ¶ 2(b), (d) (setting motion deadline and waiving D. Kan. Rule 37.1(a) pre-motion conference requirement). II. Legal Standards This Court has previously addressed motions requesting that a party responding to discovery designate additional custodians for searches of electronically stored information (“ESI”). In the case In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices & Antitrust Litigation (“EpiPen MDL”),14 the court set forth the following general principles

Free access — add to your briefcase to read the full text and ask questions with AI

Edgar v. Teva Pharmaceuticals Industries, Ltd., (D. Kan. 2025).

Edgar v. Teva Pharmaceuticals Industries, Ltd. (Edgar v. Teva Pharmaceuticals Industries, Ltd.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.